Explore the transformative trends shaping the biopharma and healthcare landscape in 2025, influenced by policy changes and technological advancements.
Pharmaceutical Executive: December 2025
Inside Brent Saunders’ return run as CEO of Bausch + Lomb—and setting the storied eye care pharma on a bold path of reinvention.
Ascension of agonist class touching all parts of the market—from science to strategy.
With patent cliffs fast approaching, asset differentiation will be king.
Amid the US reshoring push, drugmakers navigate geopolitical and supply chain risks.
Why the new wave of direct-to-consumer access represents more than a passing trend.
Will the politically fueled reforms and mandates around drug pricing reduce the complexity of the system?
Outlining the big questions and considerations for pharma companies in determining their readiness for this transformation—and achieving true “AI Advanced” status.
With prescription care changing, it’s up to benefits providers to reinforce the value of human connection in a complex system.
How pharma marketers can time brand messages to prescribers when it matters most.
Evaluating standard clinical focus through the growing financial lens.
Welcome to Pharm Exec's new guest column on navigating the geopolitical risks challenging core company strategies in today's shifting global landscape for healthcare.
Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.
How the Metsera deal extends Pfizer’s 25-year blueprint for growth.
The booming obesity drug market is redefining prescriber influence, with nurse practitioners and physician associates emerging as key decision-makers that life sciences marketers can no longer afford to overlook.
The formula for bridging scientific advancement with operational flexibility in boosting access to cell and gene therapies.
